Literature DB >> 25577624

Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis.

Ronna L Campbell1, Miguel A Park2, Michael A Kueber3, Sangil Lee3, John B Hagan2.   

Abstract

BACKGROUND: Anaphylaxis guidelines currently recommend referring patients with anaphylaxis seen in the emergency department (ED) to an allergist for follow up.
OBJECTIVE: The objective of our study was to evaluate outcomes of allergy/immunology follow-up after an ED visit for anaphylaxis.
METHODS: A retrospective health records review was conducted from April 2008 to August 2012. Charts were reviewed independently by 2 allergists to determine outcomes. Descriptive statistics with corresponding 95% CIs were calculated.
RESULTS: Among 573 patients seen in the ED who met anaphylaxis diagnostic criteria, 217 (38%) had a documented allergy/immunology follow-up. After allergy/immunology evaluation, 16 patients (7% [95% CI, 5%-12%]) had anaphylaxis ruled out. Among those with an unknown ED trigger (n = 74), 24 (32% [95% CI, 23%-44%]) had a trigger identified; and, among those who had a specific suspected ED trigger (n = 143), 9 (6% [95% CI, 3%-12%]) had a trigger identified in a category other than the one suspected in the ED, and 28 (20% [95% CI, 14%-27%]) had an unknown trigger. Thus, there were a total of 77 patients (35% [95% CI, 29%-42%]) who had an alteration in the diagnosis of anaphylaxis or trigger after allergy/immunology evaluation. Four patients (2% [95% CI, 0.7%-4.6%]) were diagnosed with a mast cell activation disorder, and 13 patients (6% [95% CI, 4%-10%]) underwent immunotherapy or desensitization.
CONCLUSION: Overall, 35% of the patients with suspected anaphylaxis in the ED had an alteration in the diagnosis or suspected trigger after allergy/immunology evaluation. These results underscore the importance of allergy/immunology follow-up after an ED visit for anaphylaxis.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaphylaxis; Emergency medicine; Follow-up studies; Immunologic desensitization; Mast cell disease

Mesh:

Year:  2014        PMID: 25577624     DOI: 10.1016/j.jaip.2014.07.011

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  10 in total

1.  Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016.

Authors:  John R Su; Pedro L Moro; Carmen S Ng; Paige W Lewis; Maria A Said; Maria V Cano
Journal:  J Allergy Clin Immunol       Date:  2019-01-14       Impact factor: 10.793

Review 2.  Overview of Allergy and Anaphylaxis.

Authors:  Timothy E Dribin; Megan S Motosue; Ronna L Campbell
Journal:  Emerg Med Clin North Am       Date:  2021-10-29       Impact factor: 2.264

3.  Risk of anaphylaxis after vaccination in children and adults.

Authors:  Michael M McNeil; Eric S Weintraub; Jonathan Duffy; Lakshmi Sukumaran; Steven J Jacobsen; Nicola P Klein; Simon J Hambidge; Grace M Lee; Lisa A Jackson; Stephanie A Irving; Jennifer P King; Elyse O Kharbanda; Robert A Bednarczyk; Frank DeStefano
Journal:  J Allergy Clin Immunol       Date:  2015-10-06       Impact factor: 10.793

Review 4.  How to manage anaphylaxis in primary care.

Authors:  Alberto Alvarez-Perea; Luciana Kase Tanno; María L Baeza
Journal:  Clin Transl Allergy       Date:  2017-12-11       Impact factor: 5.871

Review 5.  Drug-induced anaphylaxis in the emergency room.

Authors:  Tomonori Takazawa; Kiyohiro Oshima; Shigeru Saito
Journal:  Acute Med Surg       Date:  2017-05-15

Review 6.  Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities.

Authors:  Benjamin T Prince; Irene Mikhail; David R Stukus
Journal:  J Asthma Allergy       Date:  2018-06-20

7.  Management and educational status of adult anaphylaxis patients at emergency department.

Authors:  Mi-Yeong Kim; Chan Sun Park; Jae-Won Jeong
Journal:  Korean J Intern Med       Date:  2017-12-28       Impact factor: 2.884

8.  Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.

Authors:  John M Kelso
Journal:  Vaccine       Date:  2021-01-06       Impact factor: 3.641

9.  2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.

Authors:  F Estelle R Simons; Motohiro Ebisawa; Mario Sanchez-Borges; Bernard Y Thong; Margitta Worm; Luciana Kase Tanno; Richard F Lockey; Yehia M El-Gamal; Simon Ga Brown; Hae-Sim Park; Aziz Sheikh
Journal:  World Allergy Organ J       Date:  2015-10-28       Impact factor: 4.084

10.  Current state of follow-up care for patients with Hymenoptera venom anaphylaxis in southwest Germany: Major impact of early information.

Authors:  Manisha Manmohan; Sabine Müller; Michèle Myriam Rauber; Frank Koberne; H Reisch; Joachim Koster; Richard Böhm; Martin Messelken; Matthias Fischer; Thilo Jakob
Journal:  Allergo J Int       Date:  2018-01-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.